Q3-FY26 · Pranav Amin
We hope to launch another four to five products in the fourth quarter of the year. We also on track to launch our first branded product in the US in February 2026.
APLLTD / language trends
Read confidence between the lines.
Alembic Pharmaceuticals · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q3-FY26 · Shaak Amin
I think Q1 of the coming financial year is where we feel we should be back in line with the market growth rate.
Q3-FY26 · Shaak Amin
I think the whole doctor spend scenario in the context of UCMP possibly we were too conservative and extremely sensitive to it relative to the market.
Q4-FY26 · Pranavin
We are not assuming any major easing in pricing pressure, competition or supply chain volatility.
Q4-FY26 · Pranavin
The objective is not rapid scale but to build a credible and sustainable specialty platform over a period of time.
Q4-FY26 · Pranavin
I expect as I mentioned at some point we will go back up to the 20% kind of EBITDA margins over a 2-3 year period.